Ocaliva

After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe
Fierce Pharma
Mon, 12/2/24 - 07:40 pm
Intercept Pharma
Advanz Pharma
Ocaliva
liver disease
Europe
FDA declines full approval for Intercept's liver disease drug
Pharma Live
Tue, 11/12/24 - 11:10 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
liver disease
FDA Pushes Back PDUFA Dates for Amgen and Intercept
BioSpace
Fri, 10/18/24 - 11:28 am
FDA
Amgen
Lumakras
colorectal cancer
Intercept Pharma
Ocaliva
primary biliary cholangitis
FDA extends review of Obeticholic Acid (Ocaliva) sNDA for primary biliary cholangitis
HCP Live
Thu, 10/17/24 - 08:28 pm
Ocaliva
Intercept Pharma
primary biliary cholangitis
FDA
Intercept's liver med Ocaliva takes heat at FDA expert meeting, as hopes for full approval dim
Fierce Pharma
Mon, 09/16/24 - 10:54 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
US FDA staff questions confirmatory trial data for Intercept's liver disease drug
Reuters
Wed, 09/11/24 - 11:51 am
FDA
Intercept Pharma
Ocaliva
clinical trials
primary biliary cholangitis
liver disease
FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Reuters
Mon, 06/10/24 - 06:02 pm
Genfit
Ipsen
FDA
Ocaliva
primary biliary cholangitis. liver disease
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Thu, 06/22/23 - 10:46 pm
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Fri, 09/30/22 - 12:31 pm
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
Intercept sells international rights to liver drug in $400M deal
BioPharma Dive
Thu, 05/5/22 - 11:23 pm
Intercept Pharma
Advanz Pharma
Ocaliva
liver disease
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Tue, 01/4/22 - 10:25 am
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Thu, 05/27/21 - 11:06 am
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
Shedding light on Intercept’s opaque disclosure
EP Vantage
Tue, 10/13/20 - 11:13 am
Intercept Pharma
Ocaliva
NASH
drug safety
In another blow to Intercept, the FDA is investigating Ocaliva for potential risk of liver disorder
Endpoints
Fri, 10/9/20 - 10:48 am
FDA
Intercept Pharmaceuticals
Ocaliva
NASH
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25%
Xconomy
Tue, 09/1/20 - 10:45 pm
Intercept Pharma
layoffs
NASH
FDA
Ocaliva
Where Will Intercept Pharmaceuticals Be in 5 Years?
Motley Fool
Fri, 01/24/20 - 11:06 am
Intercept Pharma
Ocaliva
Poxel taking two shots at NASH as pharma waits on FDA’s Ocaliva verdict
Pharmaforum
Wed, 11/20/19 - 10:17 pm
Intercept Pharma
Poxel
NASH
Ocaliva
PXL065
PXL770
Intercept aims to triple sales force as it gears up for potential NASH launch
Fierce Pharma
Thu, 11/14/19 - 07:42 pm
Intercept Pharma
hirings
drug reps
NASH
drug launches
Ocaliva
obeticholic acid
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Intercept stock drop reflects the high bar set for NASH drugs
BioPharma Dive
Sat, 02/23/19 - 04:52 pm
Intercept Pharma
Ocaliva
NASH
clinical trials

Pages